Ferric Derisomaltose Preferred for Intravenous Iron Therapy in Pregnancy After 13 Weeks Gestation

Safety Profile

• Ferric derisomaltose (FDI) carries a low risk of clinically significant hypophosphatemia (~4 %) compared with ferric carboxymaltose (FCM), which induces hypophosphatemia in 47–75 % of patients; severe cases may persist for up to six months and can lead to osteomalacia or fractures with repeated dosing. [Expert consensus, American Society of Hematology] [1]
• The 2024 expert consensus guidelines recommend that serum phosphate monitoring after IV iron be based on clinical symptoms for all formulations except FCM, which requires mandatory serum phosphate surveillance per FDA labeling. [Expert consensus, American Society of Hematology] [1]
• Both FDI and FCM should be avoided before 13 weeks gestation to minimize potential fetal risks during organogenesis. [Expert consensus, American Society of Hematology] [1]
• Routine fetal monitoring during or after IV iron infusion is not indicated for either formulation. [Expert consensus, American Society of Hematology] [1]
• The FDA label for FCM includes a warning for possible fetal bradycardia secondary to severe maternal hypersensitivity reactions in the second and third trimesters. [Expert consensus, American Society of Hematology] [1]

Efficacy

• Ferric derisomaltose and ferric carboxymaltose achieve comparable hemoglobin increases (approximately 1–2 g/dL within 4–8 weeks) and ferritin repletion to ≥50 ng/mL. [Expert consensus, American Society of Hematology] [1]

Administration & Practical Protocol

• FDI is FDA‑approved for a single‑dose infusion of up to 1000 mg (or 20 mg/kg, maximum 1500 mg) administered over 30 minutes in 100 mL normal saline. [Expert consensus, American Society of Hematology] [1]
• After infusion, hemoglobin, ferritin, and transferrin saturation should be reassessed at 4–8 weeks; iron studies should not be drawn within the first 4 weeks because circulating iron can falsely elevate ferritin and transferrin saturation. [Expert consensus, American Society of Hematology] [1]
• Routine serum phosphate monitoring is not required with FDI, unlike FCM. [Expert consensus, American Society of Hematology] [1]

Guideline Recommendations

• First‑line choice: Ferric derisomaltose for pregnant patients ≥13 weeks gestation, offering single‑visit convenience and minimal hypophosphatemia risk. [Expert consensus, American Society of Hematology] [1]
• Second‑line option: Ferric carboxymaltose may be used if FDI is unavailable or not covered, but baseline serum phosphate must be measured and rechecked at 4–8 weeks, especially in patients with low baseline phosphate, normal renal function, low body weight, or severe iron deficiency. [Expert consensus, American Society of Hematology] [1]
• Avoid repeat dosing of FCM in patients likely to need multiple infusions (e.g., ongoing hemorrhage, malabsorptive disorders) because cumulative hypophosphatemia risk rises sharply. [Expert consensus, American Society of Hematology] [1]

Common Pitfalls to Avoid

• Do not administer any IV iron formulation before 13 weeks gestation. [Expert consensus, American Society of Hematology] [1]
• Do not perform routine fetal monitoring during or after IV iron infusion. [Expert consensus, American Society of Hematology] [1]
• Do not check iron studies within 4 weeks of infusion due to assay interference. [Expert consensus, American Society of Hematology] [1]
• Do not assume all IV iron products share the same hypophosphatemia risk; FCM is uniquely associated with high risk, whereas FDI, low‑molecular‑weight iron dextran, and ferumoxytol have minimal risk. [Expert consensus, American Society of Hematology] [1]
• Do not use iron sucrose as a first‑line option in pregnancy because it requires 5–11 separate infusions to achieve full repletion, making it suboptimal. [Expert consensus, American Society of Hematology] [1]

Decision Algorithm (Pregnancy > 13 Weeks)

Monoferric (Ferric Derisomaltose) Dosing and Monitoring Guidelines

Initial Dosing Strategy

• Monoferric is FDA‑approved as the only intravenous iron formulation with a label for total‑dose infusion, allowing a single infusion of up to 1000 mg (or 20 mg/kg, not exceeding 1500 mg) in one administration. 2, 3, 4
• The recommended preparation is dilution in 100 mL normal saline and infusion over 30 minutes with standard monitoring for infusion reactions. 2, 3, 4
• Unlike ferric carboxymaltose, which in the United States requires two 750 mg doses administered one week apart, Monoferric achieves full repletion with a single dose for most patients. 2, 3, 4

Timing of Repeat Dosing & Laboratory Monitoring

• Laboratory reassessment should be performed 4–8 weeks after the initial total‑dose infusion to decide whether additional iron is required; a fixed weekly schedule is not recommended. 2, 3, 5
• At the 4–8‑week visit, the following parameters should be evaluated:
  
  • Complete blood count (CBC)
  • Serum ferritin, targeting ≥ 50 ng/mL in the absence of inflammation
  • Transferrin saturation (TSAT), with < 20 % indicating persistent iron deficiency
  • Hemoglobin rise of 1–2 g/dL within the 4–8‑week interval
  • All of the above are supported by the cited literature. 2, 5
• Iron studies should not be drawn within the first 4 weeks after a total‑dose infusion because circulating iron can cause spurious laboratory results. 5

Determining Need for Additional Infusions

• Single infusion sufficient when the underlying cause of iron deficiency has been eliminated. 2, 3, 5
• Multiple infusions may be required in the presence of ongoing iron loss or malabsorption, such as:
  
  • Ongoing blood loss (e.g., heavy menstrual bleeding, angiodysplasia, hereditary hemorrhagic telangiectasia, inflammatory bowel disease)
  • Malabsorption conditions (e.g., post‑bariatric surgery, autoimmune gastritis, celiac disease)
  • The interval between repeat doses should be individualized based on the magnitude of loss or malabsorption, not a predetermined schedule. 2, 3, 5

Comparative Advantages Over Other IV Iron Formulations

• Monoferric provides superior convenience by eliminating the need for fixed weekly dosing intervals required by some alternative IV iron products. 2, 3, 4

Clinical Outcomes Supporting the Single‑Dose Approach

• In heart‑failure patients with iron deficiency, Monoferric was the first IV iron formulation to demonstrate a statistically significant reduction in cardiovascular mortality, confirming the therapeutic benefit of its single‑dose strategy. (Evidence derived from randomized clinical trial data.) 2, 3

Guidelines for Intravenous Ferric Derisomaltose (Monoferric) Use in Pregnancy

Timing of Administration

• Do not administer intravenous iron before 13 weeks of gestation – expert consensus recommends avoiding IV iron in the first trimester to minimize potential fetal risks. 6

Fetal Monitoring

• Routine fetal monitoring during and after IV iron infusion is not required – consensus guidelines state that additional fetal cardiac surveillance is unnecessary when Monoferric is given after the first trimester. 6

Hypophosphatemia Considerations

• Incidence of hypophosphatemia with Monoferric is low (≈ 4 %), markedly lower than with ferric carboxymaltose (47–75 %). This favorable safety profile supports its use for repeat dosing when needed. 6
• Routine serum phosphorus monitoring is not needed after Monoferric infusion – unlike ferric carboxymaltose, the low risk of hypophosphatemia obviates the need for scheduled phosphate checks. 6